Loading stock data…
Immunovant (IMVT)
$38.56-0.29 (-0.75%)
Market OpenUpdated 3:10 PM EDT
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immunovant, Inc. in the Healthcare sector is trading at $38.56 with a market capitalization of $6.8B. Wall Street consensus targets $45.76 (17 analysts), implying a +18.7% move over the next 12 months. The stock is currently near its 52-week high of $39.28, remaining 51.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +18.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$159.55M↓ | -$114.36M↑ | -$131.76M↓ | -$127.22M↓ | -$113.83M |
| Net Income | -$147.86M↓ | -$110.64M↑ | -$126.50M↓ | -$120.61M↓ | -$106.45M |
Peer Comparison
JNJUNHPFE
Fundamentals
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating pol...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.82B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-59.30%
Volume
Today's trading volume
689,296
Recent News
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benefits from a cash runway extending through launch.
Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial Commentary
Clinical trial update puts IMVT-1402 in focus Recent commentary around high response rates in Immunovant (IMVT) Phase 2 rheumatoid arthritis trial, including in patients already treated with multiple advanced therapies, has drawn fresh attention to the company lead IMVT-1402 program. See our latest analysis for Immunovant. The clinical update comes against a backdrop of a firming trend in Immunovant's share price, with a 1-month share price return of 17.35%, a 3-month share price return of...
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data
Immunovant, Inc. (NASDAQ:IMVT) ranks among the best short squeeze stocks to invest in. On May 21, H.C. Wainwright boosted Immunovant, Inc. (NASDAQ:IMVT)’s price objective to $40 from $35, keeping a Buy rating on the company’s shares. The firm noted high response rates from its Phase 2 rheumatoid arthritis trial. The trial showed that past exposure […]
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating
Immunovant, Inc. (NASDAQ:IMVT) is one of the best momentum stocks to buy according to analysts. Truist lifted the price target on Immunovant, Inc. (NASDAQ:IMVT) to $30 from $23 on May 22, maintaining a Hold rating on the shares. The firm told investors in a research note that it updated its model after the company reported fiscal […]